Merck's stock soared after its Moderna-partnered cancer vaccine cleared a key trial, adding $43 billion in market value. Investors are weighing whether this signals lasting growth or a short-lived reaction as Merck faces a looming patent cliff
On August 19, Merck stunned Wall Street with news that its personalized cancer vaccine, developed in partnership with Moderna, succeeded in a pivotal late-stage melanoma trial. The announcement sent Merck shares up roughly 12.5% by the close, marking one of the largest single-day gains in the company's history and boosting its market capitalization by about $43 billion in just hours.
The vaccine, called Intismeran, was tested alongside Merck's blockbuster immunotherapy Keytruda in patients with high-risk melanoma that had been surgically removed. Unlike traditional treatments, Intismeran is tailored to each patient's tumor mutations, training the immune system to target cancer cells more precisely. The Phase 3 INTerpath-001 trial enrolled 1,137 participants with stage 2B to stage 4 melanoma. Results showed that the combination of Intismeran and Keytruda outperformed Keytruda alone in delaying both cancer recurrence and the spread of disease to distant organs.
While the immediate financial impact from melanoma sales is significant, analysts believe the market's reaction reflects broader expectations. Goldman Sachs estimates that Intismeran could generate peak annual global sales of about $4.3 billion for melanoma, with profits split evenly between Merck and Moderna. Yet the $43 billion surge in Merck's value suggests investors are betting on the underlying mRNA technology's potential to treat other cancers, not just skin cancer.
Patent Cliff and Revenue Pressure
Merck's urgency is driven by the looming expiration of U.S. patent protection for Keytruda in 2028. Keytruda currently accounts for nearly half of Merck's total sales, and its loss of exclusivity is expected to trigger a sharp drop in revenue as generic competitors enter the market. Investors have long questioned how Merck would fill this gap. The success of Intismeran offers a possible answer, as personalized vaccines are difficult to replicate and may provide a more durable revenue stream than conventional drugs.
Wall Street responded quickly. Goldman Sachs raised its 12-month price target for Merck to $160 from $140, applying a higher earnings multiple. UBS increased its target to $175, Bank of America to $166, and JPMorgan to $150. Not all analysts were uniformly bullish-RBC Capital downgraded Merck to Sector Perform, even as it raised its target to $150, signaling that the stock's rapid appreciation may have already priced in much of the good news.
Beyond Melanoma: Broader Implications
The market's enthusiasm is not just about melanoma. The positive trial results validate the individualized mRNA approach, opening the door to similar therapies for other cancers. Merck and Moderna are already running trials in kidney, bladder, and non-small cell lung cancers, with key data expected between 2026 and 2027. A successful outcome in these areas could further strengthen Merck's position as Keytruda's exclusivity wanes.
The news also triggered a "sympathy rally" among related healthcare stocks. BioNTech, which is developing its own personalized cancer vaccines, jumped about 24%. Companies involved in manufacturing and diagnostics, such as Maravai LifeSciences and Tempus AI, also saw double-digit gains. Meanwhile, Bristol-Myers Squibb, a major player in melanoma treatment, faces a potential long-term risk to its franchise, though analysts expect the impact to be gradual and limited to earlier-stage patients.
What's Next for Investors
For investors, the key question is whether Merck's rally reflects a sustainable shift in long-term value or a short-term reaction to a single data release. The melanoma results are promising, but the full clinical data have yet to be published, and the ultimate commercial impact will depend on regulatory approvals and uptake in broader cancer types. The next major milestones include Phase 2 and Phase 3 trial results in kidney, bladder, and lung cancers over the next two years. If these trials succeed, Merck's case for replacing Keytruda revenue will be much stronger. If not, the stock could retrace some of its recent gains.
According to reporting by TheStreet, the scale of Merck's market move stands out even among recent biotech rallies. For comparison, when Micron's AI-driven memory business drew bullish analyst attention, the stock's gains were notable but did not approach the magnitude of Merck's one-day jump. (See how Micron's market surge compared.)
For now, Merck's breakthrough offers a clearer narrative for investors worried about the company's post-2028 future. But the durability of this story will depend on the success of ongoing trials and the ability to translate early clinical wins into lasting commercial results.
In 2025, Merck reported total revenue of $60.1 billion, with Keytruda accounting for $24.8 billion-roughly 41% of the company's sales. The company's R&D spending reached $13.2 billion, reflecting its push to diversify beyond Keytruda. Moderna, Merck's partner in the cancer vaccine program, reported $6.7 billion in revenue for the same period, with most sales still coming from COVID-19 vaccines. These figures underscore the financial stakes as both companies look to expand their oncology portfolios.
Personalized cancer vaccines represent a major shift in oncology, using genetic information from each patient's tumor to design targeted treatments. This approach aims to improve outcomes by focusing the immune response on unique cancer mutations, but it also introduces new challenges in manufacturing, regulatory approval, and cost. For investors, the promise of individualized therapies must be balanced against the complexity and uncertainty of bringing them to market at scale. As more data emerge from ongoing trials, the market will be watching closely to see whether this technology can deliver on its early promise-and whether it can help companies like Merck navigate the risks of patent expiration and shifting competitive dynamics.
